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Abstract:   
    Photochemical release (uncaging) of small molecule bioregulators (SMBs) such as nitric oxide 
(NO) or carbon monoxide (CO) at physiological sites offers exquisite control of timing, location 
and dosage. However, photo-uncaging faces two major problems that challenge its therapeutic 
applications: the relatively poor transmision of visible light through tissue and the need to deliver 
the appropriate precursors to the desired targets. In this brief review are discussed research 
activitites that address these issues of spatial-temporal control.   
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1. Introduction: 
 This review discusses innovative strategies for the photochemical release (uncaging) of the 
small molecule bioregulators nitric oxide (NO, aka nitrogen monoxide) and carbon monoxide (CO) 
at specific physiological sites. Localized delivery of these moieties is of interest for potential 
therapeutic applications. Key concerns include the roles of NO in the cardiovascular system, in 
antibacterial applications and in cancer therapy [1-4] as well as the roles of CO in suppressing 
inflammation, wound healing and anti-bacterial activity [5-7]. Precise spatial-temporal control is 
essential, since, for example, NO delivered systemically can induce precipitous blood pressure 
decline; indeed, this is a cause of toxic shock. Dosage control is also important, since high levels 
of NO can kill tissue by inducing cell apoptosis, but low levels may instead be proliferative [8,9].   
 The revolutionary discoveries in the late 1980’s that nitric oxide is synthesized endogenously 
and that such a simple molecule plays a plethora of roles in mammalian physiology led to the 
remarkable outpouring of research relevant to the chemical biology and biomedicine of NO. A 
key issue that emerged was what techniques could be used to deliver exogenous NO to specific 
targets. As a result, a number of compounds capable of the thermal release of NO were 
developed [10]. The story of carbon monoxide as a small molecule bioregulator (SMB) is similar. 
Although it has been known for decades that CO is generated endogenously by constitutive and 
inducible forms of the enzyme heme oxygenase [11], its bioregulatory and potentially 
therapeutic aspects were only more recently recognized. Several compounds called CORMs (CO 
releasing moieties) have been developed that are effective for the thermochemical CO release at 
physiological targets [6,12]. Interestingly, most of these CORMs are transition metal carbonyls, 
the ruthenium complex Ru(CO)3(gly)Cl (CORM-3, gly– = glycinato) being an example [13]. The foci 
of the present discussion are photochemical methodologies for the targeted release of these 
small molecule bioregulators (SMBs). 
 If the SMB in the form of a photochemical precursor is benign, it is defined as "caged". 
Electronic excitation releases or transforms it into an active or "uncaged" form. The external 
signal (light) determines the location and timing of SMB release, while the quantity of light 
absorbed controls the extent of photoreaction (i.e. dosage). Thus, photo-uncaging defines the 
location, timing and dosage of SMB delivery and has value both as an investigative tool and in 
the potential therapy of specific disease states [14-16]. An example of a therapeutic application 
would be the uncaging of a radiation sensitizer during radiotherapy. Hypoxic regions of malignant 
tumors are more g-radiation resistant than are normoxic tissue; therefore, one could reduce the 
collateral damage from such treatments by increasing the sensitivity of the targeted site [17]. NO 
is both a radiation sensitizer [18] and an exceptionally potent vasodilator [1,19], so releasing even 
nanomolar concentrations of NO at a targeted site synchronously with g-radiation treatment [20] 
would enhance the efficacy of radiotherapy [21].  
 Developing such applications requires elucidating the fundamental photochemistry and 
photophysics of effective SMB precursors as well as defining the mechanisms for transporting 
these species to the physiological sites of interest. The photo-uncaging of NO has been an active 
research topic in this laboratory [20,22-33] and others [34-43] for several decades, while the 
photo-uncaging of CO has drawn growing attention for the past decade [44-54]. These two topics 
were the subject of a several comprehensive reviews over the past several years [5, 55], so the 
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present article will not duplicate those efforts. Instead, we focus on presenting an overview of 
different photo-uncaging strategies for these two SMBs with an emphasis on studies from this 
laboratory, but also drawing attention to newer reports from other researchers. We will use the 
term “photoCORM” (photo-activated CO releasing moiety), which we coined several years ago 
for caged carbon monoxide [44], and for consistency the parallel term “photoNORM” (photo-
activated NO releasing moiety) for caged nitric oxide [55a]. 
 
2. Key Issues in photo-uncaging  
 Notably, different bioregulatory tasks require different net or steady state quantities of SMB 
release. Since small molecules can defuse away from a targeted site and/or are consumed by 
various physiological processes, the rate of the photo-uncaging process is of critical importance. 
This rate is defined for single photon excitation by the product of the quantum yield (Fi) for the 
photoreaction of interest times the intensity of light absorbed (Iabs) by the photochemical 
precursor (eq. 1),  
     Ri =  Fi x  Iabs                                                         (1) 
where Ri is the rate of the particular photochemical process of interest and FI is the efficiency by 
which excited states once formed decay along that specific pathway. (FI is unit-less.) Iabs is a 
function both of the incident light intensity Ii and of the absorbance Abs(l) by the photochemical 
precursor at the irradiation wavelength(s) lirr. (See the Appendix where the relationship between 
Iabs and photochemical rates are discussed in greater detail). Thus, one approach to enhancing 
uncaging rates is to increase the molecular absorbance by designing conjugate systems with 
strongly absorbing antennas (Scheme 1). However, it is important to recognize that such an 
antenna will only work as a photosensitizer if there are acceptor states at appropriate energies 
on the photochemical CO precursor. 
 
 
Scheme 1. A is the antenna, R is a precursor of a SMB that is uncaged once R is photosensitized by one- or two-
photon excitation.    
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 Another important issue that must be addressed when considering photochemically 
activated therapies is the wavelength of the excitation light. Photochemical reactivity is not 
sufficient for in vivo uncaging. Any biomedical application, other than subcutaneous, needs to be 
responsive to the lirr where light penetration through tissue is optimal. Such penetration is 
shallow for UV light and may be accompanied by collateral tissue damage. Transmission through 
tissue improves for longer visible wavelengths and is optimal for NIR wavelengths [56]. One can 
address this issue by modifying the optical properties of the corresponding photoNORMs and 
photoCORMs to shift the effective excitation wavelengths to lower energy. We have also 
approached this problem by developing molecular conjugates that can harvest multiple NIR 
photons to access the higher energy reactive states needed to effect the desired uncaging. 
 As noted above, photo-uncaging provides greater spatial-temporal control of SMB release. 
Nonetheless, it is clear that it would be more effective (and probably safer) to target the delivery 
of the caged compound to the organ or tissue of interest rather than overwhelming the host by 
flooding the system. So, targeting is an important consideration in the design of new compounds 
or conjugates to be used in this manner. There are a number of strategies that might be effective. 
Physical targeting may be achieved by using an implant and/or injection while biological targeting 
might be achieved by using antibodies or proteins that seek out specific tissue types. Another 
biological strategy would be to recruit immune cells, such as macrophages, loaded with a 
photochemical precursor of the desired SMB and to use this mechanism to target sites of 
inflammation such as tumors or wounds.  
 The work describe in this article is largely concerned with issues relevant to photo-uncaging 
SMBs from coordination compounds.1 Our approach focuses on two goals: (a) designing complex 
conjugate systems that utilize deep tissue penetrating near-infrared (NIR) light as the excitation 
source and (b) developing carriers for the conjugates that effectively target desired sites. 
Although we have directed our attention to NO and CO, these strategies should be applicable to 
the uncaging of any bioactive small molecule. 
 
3. Nitric oxide and carbon monoxide precursors. 
 There are a number of common issues to consider when developing an effective 
photoNORM or photoCORM or a photochemical precursor of any other SMB for therapeutic 
applications. One would be solubility in aqueous solution or at least in a medium such as aqueous 
DMSO often used for drug delivery, although as we will see below, the use of vesicles or polymer 
carriers may alleviate that requirement. Another would be reasonable stability in aerated 
aqueous media at physiological temperatures and other conditions typical to living organisms. 
While the expectation for thermally activated NO or CO precursors would be spontaneous decay 
                                                        
1 It should be noted that alternative approaches to photo-uncaging of NO and CO based on organic 
precursors are also under investigation by various researchers.  For example, nitroaromatics Ar-NO2 when 
irradiated undergo photoisomerization to the nitrito analog Ar-ONO followed by cleavage of the ArO-NO 
bond to give NO plus the phenoxy type radical ArO• (see ref. 37d, a recent review that discusses 
applications of such photochemical NO precursors in detail).  Similarly, 3-hydroxyflavone derivatives have 
been shown to eject CO when irradiated with shorter visible wavelengths (see references 52ab) 
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at known rates, a photoNORM or photoCORM should be non-toxic and relatively stable and 
should release its payload only when triggered externally with light. Another is that the metal 
containing product after payload release should not have deleterious properties, such as 
unwanted acute or long-term toxicity. Thus, it is important to characterize and identify such 
products and any secondary products formed by subsequent reactions under the conditions and 
to ascertain whether the observed physiological effects are due to SMB release or to other such 
products. Complexes of lighter metals that are more easily excreted might be preferable in terms 
of avoiding long-term toxicity.  Lastly, as noted above, photoactivity at wavelengths relevant to 
the task is needed.  
 For the promiscuous SMB nitric oxide, the biomedical rationale for controlled delivery include 
NO’s potent cardiovascular and antibacterial properties as well as potential roles in cancer 
therapy. For example, the use of NO to directly kill tumor cells has been a major focus of several 
laboratories, but one should proceed with caution in this case. As noted above, high localized 
levels of NO (>800 nm) can induce nitrosative stress and cell apoptosis, but lower levels of NO 
may instead induce tumor growth by stimulating angiogenesis [8,9]. For this reason, our 
approach draws from the view that NO delivery should be synergistic with other forms of 
treatment, such as chemotherapy [4,57] or radio-therapy [19-20]. NO is a radiation sensitizer, 
and we confirmed this in very early studies by using the Roussin’s red salt Na2[Fe2S2(NO)4] (RRS) 
as a photoNORM to deliver NO to hypoxic V79 cell cultures that thus displayed markedly 
enhanced sensitivity to g-radiation [20]. Furthermore, in a living animal, the release of the potent 
vasodilator NO, even at nanomolar concentrations, should increase the localized tissue 
oxygenation [19] and thus may indirectly enhance the radiation killing of tumor tissue.  
 Another important feature of NO photo-uncaging is that, while NO diffuses fairly readily in 
biological media, it is also readily consumed by a variety of mechanisms, including oxidation to 
nitrite and nitrate [58]. As a result, its lifetime is relatively short (seconds) and the effects of NO 
photo-uncaging are localized. 
 With regard to carbon monoxide, the most likely targets are metal (largely heme) centers, 
where CO coordination may affect cell-signaling enzymes such as transcription factors, ion 
channels and O2 transport and inhibit key processes such as the redox chain in mitochondria [5a].  
For these cases, one might use dissociation constants for CO binding to the specific proteins (for 
example, 300 - 1000 nM for globins [59]) as an estimate for the localized CO concentrations 
necessary to have significant impact.  
When faced with number of published and emerging photoNORMs and photoCORMs, one 
might ask: which of these and which method of delivery might have the most desirable 
properties?  This is a difficult question to answer, since one must consider the task for which of 
these are being proposed.  Once the task is identified, for example, treatment of a certain type 
of cancer, systematic comparison requires standardized tests to which each compound or 
conjugate and/or delivery method would be subjected, preferably by an independent laboratory. 
There are a number of issues that need to be considered including acute and long-term toxicity, 
specificity for the tissue targeted, and functional photochemical efficiency, among others.   
3.1 PhotoNORMs: Since initiating studies of NO photo-uncaging in the 1990’s, we have used 
theoretical, synthetic and mechanistic tools to develop and characterize a variety of 
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photoNORMs. The goal has been to lay the fundamental groundwork for systems that can find 
applications in mammalian physiology. There is a rich history of metal nitrosyl photochemistry, 
especially that involving metalloporphyrins [22]. Our more recent focus has been directed toward 
conjugate systems that can be triggered with the longer visible or NIR excitation wavelengths 
(lirr) that are more effective at transmission through mammalian tissue. Three such platforms 
are depicted in Figure 1: Cr(III) nitrito complexes, for example, trans-Cr(cyclam)(ONO)2+ 
("CrONO", cyclam = 1,4,8,11-tetraza-cyclotetradecane), ruthenium nitrosyls such as the salen 
complex depicted, and iron-sulfur-nitrosyl clusters like the Roussin's red salt anion (RRS). 
PhotoNORMs based on each platform were shown to be stable under physiological conditions, 
and to release NO readily upon visible light photolysis. We have also collaborated with Prof. 
Yutaka Hitomi of Doshisha University (Kyoto, Japan) who developed a manganese complex 
[Mn(NO)dpaqNO2]BPh4 (dpaqNO2 = 2-[N,N-bis(pyridin-2-ylmethyl)]-amino-Nʹ-5-nitro-quinolin-8-yl-
acetamido) [54b] that undergoes the photorelease of NO under excitation with very long visible 
irradiation wavelengths. Other ruthenium [34, 36, 40] and manganese platforms [54] have 
received attention in this field and represent some very creative synthesis efforts to design 
compounds that are photoactive at longer visible wavelengths [55a].  
    
Figure 1. Examples of photoNORMs.  
 CrONO would appear to be an ideal photoNORM. It is stable in 37 oC aqueous buffer, it 
exhibits no acute toxicity in cell-culture experiments, and it displays high quantum yields for NO 
release (FNO) at all lirr (365-546 nm) investigated [28b]. Flash photolysis experiments indicate 
that this occurs via reversible homolysis of a CrO-NO bond (Eq. 1) [28a]. As a result, net release 
of NO depends on trapping the Cr(IV) reactive intermediate by an oxidant such as O2 or a 
reductant such as glutathione (GSH). Thus, CrONO is effective toward NO photo-uncaging in both 
oxidizing and reducing media. Myography studies with porcine aorta demonstrate cardiovascular 
relaxation resulting from NO release when CrONO is irradiated but no activity from the other 
chromium containing products. 
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         (1) 
 Our photosensitization experiments and TD-DFT computations [28b] point to the reaction 
occurring from the spectrally silent, doublet metal centered, ligand field state of the Cr(III) center 
presumably populated by rapid intersystem crossing from states formed by excitation of quartet-
to-quartet, metal-centered (d-d) bands in the CrONO visible spectrum. However, these spin-
allowed transitions are Laporte forbidden and have low molar extinction coefficients. Thus, the 
rate of photochemical NO generation RNO (which equals FNO x Iabs) is inherently slow owing to 
the low value of Iabs unless the localized concentration of CrONO is high. This feature led us to 
explore various antennas with much stronger absorption cross-sections to increase light 
collection efficiency and to accelerate the RNO values by increasing Ia. Early examples from our 
laboratory demonstrated this principle with pendant aromatic chromophores as antenna for 
CrONO [60] and for Roussin’s red salt [61-63] (Figure 2). Excitation of these chromophores was 
followed by energy transfer to the attached photoNORM leading to significantly enhanced rates 
of NO release from the antenna-free photoNORM under analogous conditions and incident 
excitation intensities Ii owing to higher absorbance (Abs) at that lirr and the relationship Iabs = Ii(1-
10–Abs(l)). Notably, the fluorescence from each of these pendant chromophores is not fully 
quenched by the attached photoNORM, and thus provides a tool for tracking the location of these 
species [63]. 
 
Figure 2. Pendant chromophores on photoNORMs (Anth = anthracene; PPIX = protoporphyrin-IX; Fluor = 
fluorescein; RSE = red salt ester) 
 3.2 PhotoCORMs. The mechanisms of CO release from metal carbonyls (eq. 2) has long been 
the subject of photochemical studies [64]. However, much of the interest lay in the 
organometallic and catalysis relevant chemistry of these compounds and the photolysis 
generated intermediates [65]. As a consequence, most such investigations were carried out in 
anaerobic and anhydrous media, neither condition being very compatible for possible 
 8 
therapeutic applications. Although there were earlier studies where CO was delivered to 
biological targets via the “cold light” photolysis of the simple metal carbonyl Mn2(CO)10 [66], 
Schatzschneider and coworkers can be credited with being the first to design metal carbonyl 
complexes for this purpose [49a]. Those researchers used dimethyl sulfoxide (DMSO) solutions 
to deliver the complex salt fac-[Mn(CO)3(tpm)]PF6 (tpm = tris(pyrazolyl)methane) directly to HT29 
colon cancer cells where CO release was triggered by 365 nm light, resulting in significant 
photoinduced toxicity. This observation raises an interesting question about the goals of CO 
delivery that parallel some of the issues that plague NO delivery. If the goal is to promote wound 
healing as has been argued as an important property of exogenously applied CO [6], this would 
imply CO enhanced cell growth and motility. If the goal is anti-tumor or anti-bacterial activity, 
then cell toxicity is desired. The Janus character of these two SMBs makes controlling the timing, 
location and dosage of the delivery options all the more important. 
                                          (2)                
 Shortly after the Schatzschneider report, Dale Rimmer of this laboratory [44] completed a 
quantitative study of the water-soluble tungsten carbonyl complex Na3[W(CO)5(TPPTS)] 
(TPPTS3- is the tris(sulfonato-phenyl)phosphine trianion), which also was photoactive at near-UV 
wavelengths. Aqueous, aerobic buffer solutions of this photoCORM undergo photo-induced loss 
of one CO with a high quantum yield (FCO = 0.90 and 0.6 for lirr = 313 and 405 nm, respectively) 
followed by subsequent slow oxidation of the W(CO)4(H2O)(TPPTS)3– photoproduct to release 
one to two additional CO’s (eq. 3). In this report, Rimmer et al also described methodologies 
based on gas chromatography and on infrared spectroscopy for quantitatively measuring the 
amount of CO released under these conditions as alternative to the commonly used myoglobin 
assay [67].2 
                   (3) 
 Neither of these photoCORMs are photoactive at longer range visible or NIR wavelengths, so 
any potential therapeutic value would be restricted to surface applications. For this reason, there 
has been considerable effort at extending this type of photoactivity to longer wavelengths [45,51-
53,55] (Figure 3). To do so, one has to be attentive to the nature of the excited states that might 
lead to CO dissociation. We will take for example the group 6 M(0) complexes (M = Cr, Mo, W) of 
the type M(CO)5L or M(CO)4(LL), where L is a monodentate ligand such as pyridine (py) or a 
phosphine (R3P) and LL is a bidentate heterocycle such as 2,2’-bipyridine (bpy) or 1,10-   
                                                        
2 The commonly used method for demonstrating CO release from various CORMs and photoCORMS 
involves trapping the CO with deoxymyoglobin and measuring changes in the optical spectrum (ref 67). 
While this method is sensitive, it is not effective in aerobic media. More recently fluorescent probes for 
CO have been developed [55]. 
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Figure 3. Some photoCORM examples. 
phenanthroline (phen) (Figure 3). The same arguments apply to the group 7 M(I) complexes (M 
= Mn or Re) such as fac-M(CO)3(LL)X or fac-M(CO)3(LL)(L)+, the photochemistry of which have 
been the subject of numerous reports. The electronic transitions that dominate the lower energy 
spectra of these compounds are ligand field (LF or d–d) and metal-to-ligand charge transfer 
(MLCT) in character [64]. The metal-centered LF excited states of these low spin d6 complexes 
involve promoting electron density from p-bonding orbitals to s-antibonding orbitals with 
respect to these M-CO bonds. Thus, it is not surprising that excitation of d–d bands leads to ligand 
photodissociation with high quantum yields from LF excited states. However, carbonyls are 
strong field ligands, therefore, direct excitation of LF bands in metal carbonyls tend to occur at 
fairly high energies (UV or near-UV wavelengths). The MLCT bands have high extinction 
coefficients and can be tuned by electron withdrawing substituents to give strong visible 
absorptions. Since MLCT excitation promotes electron density from M-CO pb orbital(s) to ligand 
p*-orbital(s), it is much less obvious that the resulting MLCT excited state will be strongly labilized 
toward CO dissociation.  
 For example, Wrighton et al [68] long ago demonstrated with a series of W(CO)5(py-Y) 
complexes that tuning the MLCT excited state to energies substantially lower than the LF state 
excited state led to markedly less efficient ligand labilization as shown previously with analogous 
ruthenium complexes. While the MLCT excited states may be susceptible to an associative ligand 
substitution mechanism in a coordinating solvent [69] owing to the diminished electron density 
at the metal, the efficiency of CO labilization is likely to be significantly diminished. Indeed, much 
of the photoactivity attributed to excitation into such MLCT states may be the result of thermal 
back population into the higher energy, more reactive LF excited states. From a practical 
perspective, one may not care about the mechanism, so long as the desired CO labilization at 
longer wavelength is accomplished, but understanding these pathways would allow a more 
systematic approach to the desired outcome. 
 There various ways to address this conundrum. For example, for homologous W and Cr 
complexes or homologous Re and Mn complexes, the lighter element will express the lower LF 
excited state energies and should be more labile toward photodissociation at longer excitation 
wavelengths. Thus, while several fac-Re(CO)3(LL)(L’) complexes have demonstrated the attractive 
features as being both luminescent and photoactive toward CO dissociation [48, 51a, 70], none 
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of these show labilization at longer visible lirr. For those complexes that are also luminescent, 
Wilson and coworkers have noted some quenching by O2, raising the possibility that these might 
have bimodal action as CO and singlet oxygen generators [48]. For the Mn(I) analogs with weaker 
ligand field splitting, there are now numerous examples of CO labilization at visible lirr [51c, 55, 
71] but pushing these excitation wavelengths far into the red remains a challenge.  
 Zhi Li and coworkers from this laboratory recently introduced a different strategy to address 
the question of CO labilization from stable metal carbonyls at longer visible and NIR lirr in aerobic 
media [47]. The dinuclear rhenium-manganese carbonyl complexes (CO)5ReMn(CO)3(LL) (LL = 
phen (1), bpy (2), biquinoline (biq, 3) or phenanthroline-carboxaldehyde (phen-CHO, 4)) each 
display a strong, metal-metal bond to ligand (σMM à πL*) charge transfer (MMLCT) absorption 
band at longer wavelengths, tunable by modifying the bidentate heterocycle LL (Figure 4).  
 
Figure 4. Absorption spectra of (CO)5ReMn(CO)3(phen) (1, blue, lmax = 550 nm), (CO)5ReMn(CO)3(bpy) (2, black, 550 
nm), (CO)5ReMn(CO)3(biq) (3, red, 719 nm) and (CO)5ReMn(CO)3(phen-CHO) (4, orange, 652 nm) in ambient 
temperature, aerobic ACN showing the strong MMLCT absorption bands. (Adapted from ref. 47) 
Photolysis at red (659 nm, 1 or 2) or NIR (794 nm), nm, 3 or 4) lirr leads to reversible homolytic 
Re-Mn bond cleavage to give the corresponding mononuclear metal radicals (e.g., eq. 4) with 
quantum yields FMM as large as 0.41 for 1. In oxygenated media, these radicals are efficiently 
trapped by dioxygen to form intermediates labile toward CO release via secondary thermal 
and/or photochemical reactions as determined by gas chromatographic analysis. Exhaustive 
photolysis of 1 at 659 nm released two equivalents of CO, while no CO release was detected in 
deoxygenated solutions.  
        (4) 
 Complexes 1-4 provide proof-of-principle that long-wavelength MMLCT photoactivation of 
dinuclear complexes can trigger photochemical CO release in aerobic media, but they are not 
soluble in aqueous media. This hydrophobic character may be an advantage when used within a 
biocompatible polymer matrix or with amphiphilic polymer-based vesicles or nanocarriers as 
described below. Another option would be to modify the LL ligands to enhance aqueous 
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solubility. For example, conjugation of (CO)5ReMn(CO)3(phen-CHO), with an amine-terminated 
polyethylene glycol (PEG) oligomer (eq. 5) gives a water-soluble derivative with similar 
photochemistry. The absorption spectrum of this material displayed a broad band at ~ 569 nm, a 
shoulder at 700 nm and absorbance extending beyond 800 nm. NIR photolysis (794 nm) showed 
this material to be photoactive in aerobic, pH 7.4 solution, but FMM proved to be quite modest 
(~10-3). Similar systems are the subjects of on-going studies in this laboratory. 
(CO)5ReMn(CO)3(phen-CHO) + H2N-PEG  (CO)5ReMn(CO)3(phen-CHNPEG) + H2O     (5) 
 A related approach by Askes et al [53a] used red light (635 nm) excitation of palladium(II) 
tetraphenyl-tetrabenzoporphyrin Pd(TPTBP) to photosensitize decomposition of the 
manganese(0) dimer Mn2(CO)10. The phosphorescence from the Pd(TPTBP) triplet state is 
quenched by Mn2(CO)10 via energy (or electron) transfer. In aerobic media, this 
photosensitization leads to complete labilization of the latter to release CO with a relatively small 
net FCO (0.006). Since little CO release was seen in anaerobic media, the likely mechanism is 
cleavage of the (CO)5Mn-Mn(CO)5 bond followed by oxidative trapping of the resulting Mn(CO)5 
radicals and subsequent decomposition as shown for the dinuclear compounds described above. 
The manganese photoproduct was identified as MnO2. 
 
4. Two photon excitation:  
The key disadvantage of each of the antenna-photoNORM conjugates shown in Figure 2 is 
that the strong absorption bands for the pendant chromophores all occur in the near-UV or 
visible wavelength regions that are non-ideal for treatment in deep tissue sites. In this context, 
we initiated a program to probe the possibility of utilizing simultaneous two-photon excitation 
(TPE) as a methodology to access excited states from which NO labilization may occur, as 
illustrated in Scheme 1. Although TPE had drawn attention in photodynamic therapy circles [72], 
Steve Wecksler in this laboratory was the first to utilize this technique with a photoNORM when 
he employed an ultrafast pulsed Ti/sapphire laser operating at 800 nm to demonstrate both 
upconverted emission and NO labilization from PPIX-RSE [24]. More quantitative studies with the 
red salt ester Fluor-RSE having two pendant fluorescein chromophores demonstrated a two-
photon absorption cross section b of ~60 GM at 800 nm, about twice that for fluorescein itself 
[73]. Notably, the relationship between Iabs and Ii for simultaneous TPE is not linear as described 
above for single photon excitation. Instead Iabs is proportional to b c Ii2 , where c is the 
concentration of the substrate of interest. Consistent with this relationship, Wecksler showed 
that a log-log plot of NO production versus the intensity of the laser pulse featured a slope of 1.8 
± 0.2 [73]. TPE production of NO with NIR has since been demonstrated with other Roussin’s salt 
derivatives [74], with nitroaromatic derivatives [75], with a ruthenium nitrosyl complex [43] and 
with various nanomaterial constructs [76] 
In addition to providing the opportunity to trigger NO release using tissue-penetrating near 
infrared light, TPE also has the potential for spatial resolution. Since the rate of a TPE stimulated 
photoprocess is a function of the square of the incident intensity, it will primarily occur at the 
focal point of the excitation beam. However, light scattering in passing through a heterogeneous 
structure may restrict the utility of this technique.  
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To our knowledge, there have been no reports of NIR two-photon stimulated CO delivery 
from a photoCORM, although this would appear to be a fairly simple experiment to test with 
some of the existing systems. There has been a recent report of using NIR TPE and detection for 
in vivo sensing of CO [77]. 
 
5. Quantum dot platforms. 
We have also utilized semiconductor quantum dots (QDs) as antennas for photoNORM activation 
[26,78]. QDs offer enormous absorption cross sections for both single and two photon absorption 
as well as the ability to tune their spectra by varying the size of the semi-conductor core [79,80]. 
Furthermore, since QDs show strong photoluminescence (PL), one should be able to track their 
position in biological media. What is apparently the first example of QD photosensitization of NO 
release from a photoNORM, Dan Neuman and Alexis Ostrowski from this laboratory showed that 
CrONO quenches the PL from water soluble CdSe:ZnS and CdSeS:ZnS core:shell QDs concomitant 
with strongly enhanced NO release (Scheme 2) [26]. Peter Burks et al followed this study by 
probing the PL quenching and ultra-fast laser transient absorption kinetics for CdSeS:ZnS 
core:shell QDs in the presence of various chromium(III) complexes [81]. These properties were 
best interpreted in terms of Förster resonance energy transfer (FRET) from the QD band edge 
excited state to sensitize the spin-allowed quartet-to-quartet transition in these Cr(III) 
complexes. Subsequent intersystem crossing would give the Cr(III) doublet LF state discerned by 
time dependent density functional theory (DFT) calculations to be the reactive state (Figure 5) 
responsible for NO dissociation.  
 
Scheme 2. QD to CrONO energy transfer.  The surface ligands are dihydrolipoates to enhance water solubility [26]. 
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Figure 5. Energy level diagram for the photosensitization of trans-Cr(cyclam)(ONO)2+ by CdSe:ZnS core shell quantum 
dots in aqueous solution.  
 In collaboration with Roberto Santana da Silva, we demonstrated similar photo-sensitization 
of NO release by CdTe QDs (capped with mercaptopropionic acid to make them water soluble) 
and a ruthenium photoNORM cis-[Ru-(NO)(4-ampy)(bpy)2]3+ (4-ampy = 4-aminopyridine) leading 
to markedly increased NO release with 530 nm excitation [78]. In this case, since there was little 
overlap of the QD emission and the Ru absorption bands, it was proposed that a charge transfer, 
rather than FRET mechanism was responsible. Transient spectra changes using ultrafast laser 
flash photolysis were consistent with this analysis. We have observed analogous photocatalytic 
charge transfer uncaging of carbon disulfide from the 1,1-dithiooxalate anion as photosensitized 
by CdSe QDs (eq. 6) [82]. 
          (6) 
A problem with such QDs in terms of potential applications in human biology is the toxicity 
of cadmium. For this reason, we and others have turned attention to the synthesis of conjugates 
of photoNORMs to nanomaterials that are potentially less toxic. Wan and coworkers, for example 
have reported the synthesis of water dispersible nanoparticles (NPs) consisting of a Ag2S QD cores 
conjugated to S-nitrosothiol derivatives such as the glutathiose derivative shown in Scheme 3 
[83]. These nanomaterials were bifunctional since UV-visible irradiation (365 or 488 nm) of the 
conjugates in aqueous media resulted in NO release, while 808 nm excitation led to NIR PL that 
could be readily imaged with in vitro cells and in vivo in mice. The two processes were decoupled 
with the NO release attributed to the direct excitation of the RSNO functionality, which has been 
previously shown to be exceptionally photolabile to visible range excitation [84]. Virtually no 
nitric oxide release was seen upon NIR excitation.  
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Scheme 3. Illustration of a nanomaterial consisting of a Ag2S QD conjugated to a S-nitroso derivative of 
glutathiose showing how UV/Vis excitation leads to NO release while 808 nm excitation leads to imageable 
NIR fluorescence. (Reprinted with permission from ref. 83a, Copyright 2013, American Chemical Society) 
 A seemingly ideal QD semiconductor material for biological applications would be carbon; 
thus, there has been a growing interest in graphitic nanomaterial photosensitizers [85-87]. For 
example, Scheme 4 illustrates a conjugate of carbon quantum dots (CQDs) linked covalently to a 
nitroaniline-based NO photodonor prepared by Sortino and coworkers [85]. Single photon 
excitation was limited by the absorption of this conjugate at wavelengths less than 450 nm. 
However, the high two photon cross section of these CQDs allowed NO photo–uncaging via FRET 
activation of the nitroaniline derivative after TPE with 800 nm light. This combination proved 
toxic to HeLa cells in vitro and after intra-tumoral injection modestly reduced the size of hypoxic 
human pancreatic BxPC-3 tumors induced in Balb/c SCID mice. 
 
Scheme 4. Illustration of a carbon quantum dot decorated with nitroaniline derivatives that are 
photoactivated by FRET from the CQD excited state formed by single or two photon excitation. (Adapted 
with permission from ref. 85)  
 Lui et al [86] have described several luminescent nanoplatforms consisting of N-doped 
graphene QDs (GQDs, diameters 7-10 nm) functionalized with a ruthenium photoNORM (77,78). 
For example, the nanoplatform illustrated in Scheme 5 is also decorated with a 
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triphenylphosphonium moiety that, when administered to HeLa cancer cells, directs this platform 
to localize in the mitochondria [86]. The in vitro generation of nitric oxide in these cells upon 808 
nm irradiation was demonstrated using the intracellular NO-sensitive fluorescent probe, DAF-FM 
DA (4-amino-5-methylamino-2',7'-difluorofluorescein diacetate). Furthermore, this treatment 
significantly decreased the viability of these HeLa cells by triggering apoptosis. Similar effects 
were noted after intratumoral injection of this platform into HeLa tumor-bearing mice followed 
by 808 nm irradiation. Notably, continuous 808 nm irradiation of a 1 mg mL-1 suspension of this 
nanoplatform in aqueous buffer at a 1 watt per cm–2 power density for 10 min led to a substantial 
temperature change in the bulk solvent. Such a photothermal effect needs to be considered 
whenever such absorbers are subjected to continuous NIR excitation. The total energy deposited 
at a site is likely to be much larger under such conditions than when using a pulsed laser with 
much higher peak power, but lower average power.  
 
Scheme 5. Cartoon illustrating the covalent attachment of both a ruthenium photoNORM and a 
triphenylphosphonium moiety on a N-doped graphene QD. (Adapted with permission from reference 86). 
The same research team has also recently reported another platform based on N-doped 
graphene QDs decorated with a ruthenium photoNORM and a galactose derivative that 
selectively targets liver cancer cells over normal liver cells (87). 
Po-Ju Huang of this laboratory has also developed a nano-carrier with N-doped graphene QDs 
as the photo-active cores with 4 nm diameters and 1.4 nm thick [88]. Through amide coupling of 
surface carboxylates with oleylamine, the resulting GQDs had lipophilic surface domains that 
could be assembled with the amphiphilic biotinylated phospholipid-functionalized poly(ethylene 
glycol) DSPE-PEG to give the nanocarrier GQD@ DSPE-PEG. This construct was surface modified 
with HIV-1-Trans-Activator of Transcription (TAT) peptide, a well-known [89] cell-penetrating 
peptide, via biotin-streptavidin-biotin assembly strategy. Nano-carriers surface modified in this 
manner can overcome cellular membrane barriers to enter cells (Scheme 6). The lipophilic 
domains of the these nano-carriers were loaded with a hydrophobic CrONO derivative trans-
[Cr(PetA)(ONO)2]BPh4 (PetACrONO, PetA = 5,12-dimethyl-7,14-diphenyl-1,4,8,11-tetraaza-
cyclotetradecane). The fully loaded nanocarriers largely fell in the 20-70 nm size range.  
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PetACrONO  
An aqueous suspension of these GQD@DSPE-PEG nano-carriers loaded with PetACrONO in 
pH 7.4 PBS solution release NO upon continuous excitation at 794 nm with a diode laser. Notably, 
in solution this Cr(III) complex displays no absorbance at 794 nm nor is it photoactive at this 
wavelength. The released NO was quantified as functions of irradiation time and of laser power 
density using a Sievers nitric oxide analyzer (NOA). The quantity of NO generated was 
approximately linear in both laser power and irradiation time [88]. These observations argue 
against NO release from the incorporated PetACrONO occurring through multi-photon processes 
sensitized by the GQD cores. Thus, it seems likely that a photothermal process is triggering the 
NO release from the photoNORMs located in the lipophilic domains. 
   
Scheme 6. Illustration of the loading of PetACrONO into the lipophilic domains of the nanocarrier GQDs@DSPE-PEG, 
the surface of which can be conjugated with biotinlyated TAT peptide to enhance the internalization into cancer cells 
(Reproduced with permission from ref. 88) 
 A preliminary in vitro study showed that TAT modified GQD@DSPE-PEG nanocarriers 
containing PetACrONO can be delivered into HeLa cells [88]. The HeLa cells had been pretreated 
with the nitric oxide synthase inhibitor, L-N-nitroarginine methyl ester to minimize native NO 
generation. After 2 min irradiation of cells loaded with these NO-nanocarriers at 794 nm with 
power density of 13 W/cm2, a strong fluorescent signal from the intracellular NO-probe DAF-FM 
DA was evident. In contrast, there was negligible fluorescence from control experiments 
including those cells with the PetACrONO containing nanocarriers that were not subjected to NIR 
excitation.  
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 Ruggi and Zobi [90] have described the synthesis and photochemistry of several conjugates 
between CdSe:ZnS core shell QDs and Mn(I) photoCORMs of the type fac-Mn(CO)3(LL)Br, where 
LL is a bipyridine derivative. Carboxylate or dithiocarbamate functionalities on the LL ligand 
facilitated attachment to the surface of QDs with a band edge absorption at 504 nm. Visible 
excitation of these QD-photoCORM conjugates at 510 nm, led to CO photodissociation at rates 2 
to 6-fold faster than the analogous photoreactions of these fac-Mn(CO)3(LL)Br photoCORMs 
alone, presumably because of the much higher absorbance at this wavelength for the former. 
This study was the first and, apparently, the only report to date of photoCORM sensitization by 
a semiconductor QD [91]. 
 
6. Polymer, metallic and other nanomaterial platforms:  
 Another nano-material strategy for the delivery of photoNORMs is to utilize organic polymers 
materials as nanocarriers for the caged SMB precursors. Tfouni et al demonstrated this by 
encapsulating the ruthenium nitrosyl photoNORMs trans-Ru(NO)Cl(cyclam)](PF6)2 and 
[Ru(NO)(Hedta)] (Hedta = ethylenediaminetetraacetic acid) in poly(D,L-lactic-co-glycolic) acid 
(PLGA) nanoparticles (220-820 nm diameter) [34d]. The loaded PLGA NPs showed lower in vitro 
toxicity against melanoma cells relative to the same ruthenium nitrosyls in solution. UV 
irradiation (300-350 nm) led to NO release and considerable surface damage to these cells with 
rupture of the plasma membranes indicating that NO generated in the PLGA NPs can readily 
escape.   
Sortino and coworkers have very creatively engineered polymer nanomaterials containing 
various nitoaromatics as photoNORMs as well as combinations of various fluorophores [37b, 37c, 
37e, 37f]. In this manner, these researchers were able to combine several functions including NO 
release, photodynamic production of singlet oxygen, and theranostic reporting of the location 
and timing of NO release. These studies have been recently the subject of an extensive review by 
Fraix, Marino and Sortino [37d].  
 Liposomes, although somewhat larger than typical nanoparticles, have also been examined 
as possible vehicles for delivering photoNORMs to specific targets.  For example, Ostrowski et al 
[63]   encapsulated the BF4– salts of CrONO and the anthracene tethered complex Anth-CrONO 
(Figures 1 & 2) in phosphatidylcholine liposomes (Scheme 7). The fluorescence of Anth-CrONO 
can be detected through the liposomes, thus these vessels can be tracked simultaneously with 
therapeutic NO release. The quantum yield for net NO release from these liposome-encapsulated 
complexes in oxygenated solution proved to be considerably larger for than for the same species 
free in solution, presumably owing to changes in the dynamics of post photolysis reactions that 
scavenge this photoproduct. Since the enhanced permeation and retention (EPR) effect 
accumulates nano-sized particles such as liposomes in tumors (92), liposomes loaded with a 
luminescent photoNORM have theranostic potential. 
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Scheme 7. Illustration of a liposome encapsulating the luminescent salt [Anth-CrONO]BF4 .  Photolysis leads both to 
NO release and detectable emission. (Reprinted with permission from ref 63. Copyright 2012 American Chemical 
Society). 
 Nakanishi et al (93) have described another example of a photoNORM loaded liposome.  In 
this case, the lipophilic Ru salen complex [Ru(L)Cl(NO)] with pendant cholesterol groups (L = N,Nʹ-
ethylene-bis(4-cholesteryl-hemisuccinate-salicylideneamine) was incorporated into bilayers of a 
1,2-ditetradecanoyl-sn-glycero-3-phospho-(1ʹ-rac-glycerol) liposome.  Irradiation at 495 nm led 
to NO release detected using the NO probe DAF-2 in coexisting liposomes.   
Several features of metallic nanoparticles are attractive as platforms for drug delivery. One is 
the affinity of metals such as gold for thiols that facilitates the simultaneous assembly of different 
theranostic functionalities, such as bioimaging and targeted drug delivery in a single NP [94]. So 
far, applications of this technology to NO uncaging are relatively limited, but the plasmonic 
absorptions of gold NPs in the NIR and the resulting photothermal effects offer some very 
interesting possibilities in this regard. 
Sortino and coworkers were the first to explore NO release from systems constructed from 
metallic nanoparticles when they used platinum NPs as the core to assemble a polyfunctional 
system containing both a porphyrin based fluorophore and a derivative of nitroaniline as a 
photoNORM [95,96]. Irradiation of this ensemble in pH 7.4 aqueous solution at 400 nm gave both 
NO release and red fluorescence. They have extended this approach by using gold NPs as the 
core for sophisticated water-soluble ensembles for photo-activated NO release [96]. In each case, 
the photoNORM was a derivative of nitroaniline and the activating light was in the visible range 
(> 400 nm).  
In collaboration with colleague Norbert Reich, Liz Levy of this laboratory utilized the NIR 
plasmonic absorption properties of hollow gold nanoshells (HGNs, ~65 nm diameters) to photo-
uncage NO from an ensemble built on a HGN core [32]. The nitric oxide precursor in this case was 
TCF, a thiol functionalized derivative of cupferron, (ammonium N-nitroso(4-mercapto-
methylphenyl)hydroxylamine) coordinated to the HGN surface. Aqueous solubility was achieved 
by adding thiolated polyethylene glycol (TPEG) ligands [97] The resulting TCF-HGN-TPEG 
conjugate displayed a broad, very strong absorption band centered at ~750 nm attributed to the 
plasmonic transition of the HGN core. Nitric oxide release was triggered by 800 nm excitation of 
this conjugate (Scheme 8) using the pulses from an ultra-fast laser. The high peak intensities of 
the laser pulses are exceptionally effective in the rapid heating of gold NPs with NIR light [94a], 
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so we attribute this reactivity to the photothermal decomposition of the TCF. Remarkably, 
aqueous solutions of these TCF-HGN-TPEG conjugates could also be activated by a continuous 
diode laser operating at 800 nm, although it was necessary to focus the beam to a diameter of 
0.9 mm in order to generate sufficient intensity for this nonlinear process.    
 
Scheme 8. HGN surfaces are coated by co-absorption of TCF and TPEG or TPEGRP. The TPEGRP includes a cell-
targeting peptide. Laser excitation (800 nm) of these conjugates results in NO release with spatial-temporal 
control. 
The HGN platform also allowed for functionalizing the gold surface with a thiolated 
polyethylene glycol modified to include the terminally bound targeting peptide RPARPAR 
(TPEGRP). The RPARPAR peptide mediates cellular internalization via endocytosis only for cells 
that overexpress the Neuropilin-1 receptor [98]. Thus, the TCF–HGN–TPEGRP conjugates were 
readily internalized by PPC-1 or 22Rv1 prostate carcinoma cells, but not by HeLa cells that lack 
this receptor. Photoexcitation of 22Rv1 containing the internalized TCF–HGN–TPEGRP conjugates 
demonstrated NO release as reported by the intracellular NO-probe DAF-FM DA [32].  
Although not strictly a photothermal effect, Janiak and coworkers [99] prepared conjugates 
consisting of Fe2O3 nanoparticles to which they have attached the ruthenium carbonyl complex 
Ru(CO)3(L)Cl, where L is a phenylalaninato derivative. These are coated with dextrin to enhance 
water solubility. At physiological temperatures Ru(CO)3(L)Cl conjugate releases CO slowly (that 
is, it is a CORM), however the rate of CO release is markedly accelerated when the iron oxide 
nanoparticles of these ensembles are heated by an alternating current magnetic field. 
A somewhat different approach was taken by Furukawa and coworkers [100], who 
immobilized the manganese photoCORM fac-MnBr(bpydc)(CO)3 (bpydc = 5,5’-dicarboxylate-2,2’-
bipyridine) into a nanocrystalline Zr(IV)-based metal–organic framework (MOF). The resulting 
MOF crystals were photoactive toward carbon monoxide release when irradiated with 460 nm 
light. These MOF crystals were suspended in a biocompatible polymer matrix (PDMS) upon which 
were grown HeLa cells. Visible photolysis of this matrix led to CO release and up take into the 
cells as demonstrated using the intracellular fluorescent CO-probe COP-1 [101]. The 
photosensitive polymer incorporated MOFs with high CO payloads would appear to be 
appropriate for localized applications as implants or other devices. 
 Schoenfisch and coworkers [102], among others [103], have used silica nanoparticles as a 
delivery method for NO-releasing compounds.  Several recent studies (29, 104, 105) have 
demonstrated the use of similar silica-based NPs for photoNORM and photoCORM delivery 
agents. As will be discussed in the next section, Garcia et al (29) prepared mesoporous silica NPs 
with a NIR-photoactive core consisting of a upconverting NP (UCNP Figure 6. This was loaded 
with the photoNORM Roussin's black salt (Na[Fe4S3(NO)7] then coated with an amphiphilic 
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polymer to seal the pores. The result was a water-soluble nanocarrier that released NO upon 
excitation at 980 nm.  
 
Figure 6.   TEM image of a mesoporous silica nanoparticle with an upconverting NP core (adapted from ref. 29)  
 A different approach was taken by the Sortino group (104) who embedded luminescent 
carbon quantum dots into amine terminated mesoporous silica NPs.  This material was then 
functionalized by reacting with 4-chloro-2-trifluoromethyl-nitrobenzene to give a covalently 
linked nitroaniline derivative on the surface of these ~400 nm diameter constructs. 
Photoexcitation of an aqueous suspension of these conjugates with 405 nm light led to a 
bleaching of characteristic absorption band of the nitroaniline derivative and release of NO.  On 
the same time scale, the CQD emission, which was largely quenched in the nitroaniline derivative, 
was restored thereby acting as an optical reporter of NO release.  
 In a similar fashion, Chakraborty et al (105) prepared mesoporous silica nanoparticles (100 
nm diameter) packed with a designed photoCORM fac-[Re(CO)3(pbt)(PPh3)](CF3SO3) that is 
strongly luminescent at 605 nm when excited in the UV. In vitro experiments showed that these 
constructs were endocytosed into human breast cancer cells (MDA-MB-231) where they were 
visualized by their luminescence. Exposure of the cells to UV excitation led to reduced emission 
owing to CO release from the Re(I) compound and to death of the MDA-MB-231 cells attributed 
to CO-induced toxicity.  
   
7. Upconverting nanoparticles (UCNPs) antennas. 
Lanthanide-doped UCNPs represent an exciting change in the landscape of biological imaging 
and photosensitization owing to their unique optical properties and low toxicities [106]. These 
can effect NIR-to-visible (or UV) up-conversion by sequential multi-photon excitation which is 
inherently more efficient than simultaneous two photon excitation [107]. In the core UCNPs, one 
lanthanide ion (Ln3+), typically Yb3+, acts as the light absorbing sensitizer while a second, such as 
Er3+ or Tm3+, is the emitter after sequential energy transfer from the sensitizer. Thus, 
upconversion requires much lower light intensities than does simultaneous TPE, so one can use 
relatively simple NIR diode lasers operating in pulsed or continuous wave (CW) modes to effect 
such excitation. The upconversion efficiency remains a function of In  with n > 1, so the excitation 
efficiency is greatest at the focal point and spatial resolution remains a potential feature. Thus, 
the ability to effect uncaging with NIR light from a simple CW diode laser is a potential game 
changer in photo-activated drug delivery [108].  
 21 
Recognizing that UCNPs would be attractive as NIR photosensitizers with photoNORMs, John 
Garcia of this laboratory, in collaboration with colleague Galen Stucky and Fan Zhang and 
Dongyuan Zhao of Fudan U used, for the first time, UCNPs to photosensitize NO uncaging with 
NIR light [29]. These UCNPs, composed of NaYF4:Yb/Er cores (~10 nm) coated with NaYF4 and 
mesoporous silica shells displayed bright visible luminescence upon 980 nm irradiation with a CW 
diode laser. The mesoporous silica shell was infused with the photoNORM Roussin's black salt 
(RBS), then capped with poly(allylamine hydrochloride) to inhibit RBS diffusion into the solution. 
This procedure gave a nano-carrier that released biologically relevant concentrations of NO when 
photolyzed at 980 nm in aqueous solution owing to the overlap of the upconverted emission and 
the RBS absorption spectrum (Figure 7). Notably, RBS undergoes NO photodissociation when 
irradiated directly with visible light (eq. 7) [20] but is not when irradiated directly at NIR 
wavelengths [29].  
                   (7) 
 
 
Figure 7. The overlap of the upconversion emission spectrum water soluble NaYF4:Yb/Er@SiO2@mpSiO2 
UCNP with the absorption spectrum of RBS. Insert: Illustration of a nanocarrier with a UCNP core and a 
mesoporous silica shell loaded with the photoNORM RBS and capped with an amphiphilic polymer. NIR 
photolysis results in NO uncaging. 
 Although the mechanism has not been studied in detail, energy transfer likely occurs by 
visible light emission from the UCNP followed by reabsorption by the photoNORM (the so-called 
“trivial” mechanism). While inefficient, this pathway simply requires that the precursor have 
strong absorption bands that overlap with the UCNP emissions as shown in Figure 7. This simple 
requirement led Peter Burks and John Garcia of this laboratory to prepare mm-sized polymer 
disks from biocompatible polydimethylsiloxane (PDMS) in which UCNP is simply suspended in the 
curing polymer and the photoNORM RBS was infused into the cured disk (Figure 8). NO release 
as measured with the NOA was effected by 980 nm irradiation with the CW diode laser, although 
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in order to obtain reproducible data, they developed a device that scans the entire disk with an 
oscillating beam (Figure 9) [30]. Furthermore, they demonstrated that NIR excitation triggered 
photo-uncaging from these devices even through tissue filters [30]. One can envision using such 
materials as implants.  
                                
Figure 8. PDMS disks (5 x 2 mm). Left: blank disk. Right: disk loaded with UNCPs and RBS. Pictured with a US 1 cent 
coin to indicate relative size.  
 
 
Figure 9. Apparatus for evaluating NO release from photoNORMs in polymer disks. The oscillating mirrors are 
controlled in such a manner that the laser beam systematically samples the entire sample. 
 We have extended these studies by demonstrating NO release from disks prepared with 
different commercial formulations of biocompatible silicon polymers in which were suspended 
Nd3+ sensitized UCNPs (β-NaYF4:Tm/Nd/Yb/Gd@NaYF4:Nd) that can be activated at 800 nm. The 
photoNORM infused into the disk was the hydrophobic complex PetACrONO [109]. Independent 
studies by Ostrowski et al [110] with related silicone polymer disks containing UCNPs and the 
hydrophobic CrONO salt trans-[Cr(cyclam)(ONO)2]BPh4 gave similar results. The latter 
researchers also made the important discovery that the facility of NO escape from the polymer 
was quite sensitive to the manner in which the photoNORM was incorporated into the disk.  
 Multiphoton excitation of UCNPs also offers a method for the NIR photoexcitation of 
photoCORMs. For example, the Mn(I) photoCORM trans-Mn(CO)2(PPh3)2(bpy)+ displays strong 
visible range absorptions, 470 nm photolysis of which leads to facile release of both CO’s with a 
moderately high quantum yield (0.26). The spectrum is well suited for matching the emission 
from NaYF4(Yb20Tm0.2) UCNPs (Figure 10). To take advantage, Agustin Pierri from this laboratory 
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in collaboration with Nanfeng Zheng of Xiamen University [46] assembled nano-carriers 
consisting of UCNP cores terminated with hydrophobic oleate surface ligands made water-
soluble by coating with an amphiphilic phospholipid-functionalized poly-(ethylene glycol) (DSPE-
PEG 2000) (Figure 11). The resulting nano-carrier provided a lipid-like interior into which the 
hydrophobic salt trans-[Mn(CO)2(PPh3)2(bpy)](CF3SO3) was readily infused to bring together the 
UCNP NIR antenna and a hydrophobic photoCORM in a stable, water-soluble ensemble. Dynamic 
light scattering measurements showed these to have diameters largely in the 16–30 nm range. 
NIR excitation (980 nm) of an aqueous solution containing the resulting loaded nano-carrier led 
to CO release as confirmed by gas chromatography [44] and by trapping with deoxymyoglobin 
[67]. 
 
Figure 10. Absorption spectrum for trans-Mn(CO)2(PPh3)2(bpy)+ and emission spectrum of NaGdF4:Tm,Yb@NaGdF4 
UCNPs (lirr = 980 nm). 
 
Figure 11. Water-soluble photoCORM nano-carriers with a UCNP core 
 A similar approach to activating a photoCORM by NIR-to-visible upconversion has recently 
been reported by X. Liu and coworkers [111]. These researchers constructed a nanocarrier with 
a NaYF4:Yb/Er UCNP core coated with silica and surface functionalized with thiol groups on the 
by treating the NaYF4:Yb/Er-SiO2 UCNPs with 3-mercaptopropyltrimethoxysilane. Reaction of the 
surface SH groups with Fe(h5-C5H5)(CO)2I led to the fixation of “Fe(h5-C5H5)(CO)2” presumably by 
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thiol displacement of the coordinated iodide as evidenced by the IR spectra of the resulting 
conjugates. NIR photolysis of the NaYF4:Yb/Er-SiO2-CORM conjugates with 980 nm light led to 
visible emission bands like those seen in Figure 6 that overlap with the absorption spectrum of 
the iron carbonyl unit. Photo-induced CO release was evidenced by changes in the IR spectrum, 
but it does not appear that the freed CO was directly measured. The NaYF4:Yb/Er-SiO2-CORM 
conjugate was not toxic to human umbilical vein epithelial cells (HUVEC) or mouse fibroblast cells 
(L929) nor did it prove phototoxic when irradiated at 980 nm.  
 
8. Biological targeting 
 While NIR excitation allows one to define location and timing of SMB uncaging in tissue, 
another key task is to improve transport of the precursor-antenna conjugates to the desired 
targets. Such targeting can be accomplished by direct injection into the desired site or by 
implanting a device such as a PDMS disk such as shown in Figure 7 or some other solid material 
incorporating the caged SMB. Indeed, if such an implant were attached to an optical fiber [51b, 
112], there would be less of a restriction to making the specific photoNORM or photoCORM 
responsive to tissue-transmitting wavelengths. More elegant strategies would be to recruit the 
specificity of biological mechanisms to target the tissues of interest. Recent examples include 
building conjugates with a triphenylphosphonium [86] or folic acid groups to address receptors 
overexpressed by certain cells [113].   
 In this laboratory, we approached this challenge in two ways. The first was introduced above, 
namely to use targeting peptides to direct water-soluble nanoparticle carriers to cell types with 
specific receptors [32]. In that example, a conjugate was assembled on the hollow gold 
nanoparticle platform that included the terminally bound targeting peptide RPARPAR that 
mediates cellular internalization only for cells that overexpress the Neuropilin-1 receptor [99]. In 
vitro microscopy experiments showed these conjugates to be readily internalized by PPC-1 or 
22Rv1 prostate cancer cells, but not by HeLa cells lacking this receptor. NIR photolysis of 
nanocarriers internalized in 22Rv1 clearly demonstrated intracellular NO-release [32]. Depending 
on the sequences, such RGD peptides target specific cell types, both in vitro and in vivo [99,114]. 
Tirrell et al, for example, used micelles constructed of peptide terminated polymers for targeted 
delivery of chemotherapeutic agents to malignant giomas, thereby minimizing other side effects 
[115]. Simply stated, these proof-of-principle precedents suggest that decorating other 
photoNORM or photoCORM nanocarriers with the appropriate targeting peptide may greatly 
enhance delivery specificity. 
 The second approach is to recruit immune cells to serve as Trojan horses to carry the desired 
payload to the targeted tissue (Scheme 9) [33]. In collaboration with BioEngineering colleague  
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Scheme 9. Trojan horse mechanism using macrophages to transport PLGA microcarriers loaded with UCNPs and a 
photoNORM to tumors or other sites of inflammation. 
Samir Mitragotri, Michael Evans and Po-Ju Huang in this laboratory initiated a program to probe 
the ability of macrophages and monocytes to carry loaded micron-sized polymer carriers to 
target sites [33]. Our micro-carriers are miniaturized versions of the biocompatible polymer disks 
described above [30]. Earlier work showed that these immune cells will ingest micron-sized 
particles and transport them to sites of inflammation [116,117]. Unlike other circulatory cells, 
monocytes can cross typically impenetrable barriers such as the blood brain barrier [118] and can 
accumulate in difficult-to-access tissues, such as tumors [119,120]. Tumor hypoxia generates 
inflammatory signals that recruit monocytes and macrophages from the blood via chemotaxis.. 
Thus, our premise was that these micro-carriers can be loaded with a photoNORM and UCNP 
antennas and that immune cells can be recruited to serve as Trojan horses to transport them. 
Once the precursors are deposited in the targeted tissue, the relevant SMB is uncaged by NIR 
excitation.  
 To address this proposal, we prepared micro-carriers from the bio-degradable polymer PLGA 
and loaded these with UCNPs and hydrophobic photoNORMs such as PetACrONO and the 
[Mn(NO)dpaqNO2]BPh4 provided by Yutaka Hitomi [54b]. NIR irradiation of aqueous suspensions 
of these microparticles released NO as measured using an NOA and demonstrated that NO can 
escape the particles. Furthermore, confocal microscopy showed that murine macrophages ingest 
these micron sized PLGA beads and that ingestion efficiency improved significantly when IgG 
antibodies were incorporated in the preparation of these particles. Photolysis of macrophages 
containing ingested, loaded micro-carriers leads to intracellular NO release as imaged using the 
DAF-FM-2DA fluorescent reporter. 
 The loaded microparticles proved to be non-toxic to their bone marrow derived macrophage 
hosts in the absence of light. These cells also maintained their chemotactic ability to traverse an 
in vitro brain barrier transendothelial model. Furthermore, this study showed that the 
microparticle-carrying macrophages deeply penetrate into NIH-3T3/4T1 spheroid tumor models 
that were grown for this purpose [33]. Both the [Mn(NO)dpaqNO2]BPh4 photoNORM and the Nd-
UCNPs are activated by NIR excitation at ~800 nm; thus, simultaneous therapeutic NO delivery 
and photoluminescence (PL) imaging can be achieved with a NIR diode laser. Irradiation of the 
infiltrated tumor spheroids with 794 nm light led to quantifiable NO release and emission from 
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the Nd-UCNPs that gave images of microparticle location. When the NIR light doses were 
relatively low, there was a reduction in hypoxia inducible factor 1 alpha (HIF-1α) levels in the 
tumor spheroids. In contrast, high doses led to cell death, presumably by triggering an apoptosis 
mechanism. Thus, we were able to recruit macrophages as Trojan Horses to carry PLGA-based 
microparticles with a NIR-activated theranostic payload into a tumor model and were able to 
control biological response by varying the amount of irradiation, thus the dosage of SMB. This 
strategy addresses challenges often faced with therapeutic administration of NO and offers 
multiple treatment pathways applicable to the uncaging of other small molecule bioregulators 
and/or therapeutic drugs. 
 
9. Summary  
 Research into the uncaging of NO and CO has progressed from designing new photoNORMs 
and photoCORMs that can deliver these payloads with controllable photochemical rates to 
developing strategies to release these SMBs at specific physiological targets. The general lessons 
learned define parameters that allow one to use longer wavelength excitation to activate photo-
uncaging and to recruit biological mechanisms to facilitate such specificity.  Such lessons are 
readily translated to the delivery of other biologically active small molecules. It remains to be 
seen when these accomplishments will transition into in vivo studies and eventually to the clinic.   
 
 
 
10. Abbreviations: 
bpy 2,2’-bipyridine 
CORM Carbon monoxide releasing moiety 
CrONO trans-CrIII(cyclam)(ONO)2+ 
CW Continuous wave 
cyclam 1,4,8,11 tetraazacyclotetradecane 
DAF-FM DA  4-amino-5-methylamino-2',7'-difluorofluorescein diacetate 
DFT Density functional theory 
DMSO Dimethylsulfoxide 
dpaqNO2  2-[N,N-bis(pyridin-2-ylmethyl)]-amino-Nʹ-5-nitro-quinolin-8-yl-acetamido) 
DSPE-PEG Phospholipid-functionalized poly(ethylene glycol)  
ES Excited state 
Fluor Fluorescein 
FRET Förster resonance energy transfer 
gly–  Glycinato 
GM Goeppert-Mayer unit for two photon absorption 
GSH Glutathione 
HGN Hollow gold nanosphere 
HO Heme oxygenase 
Ii Incident light intensity 
Iabs Intensity of light absorbed 
IR Infrared 
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LF Ligand field 
Mb Myoglobin 
MLCT Metal to ligand charge transfer 
NIR Near infrared 
NMR Nuclear magnetic resonance 
NOA Sievers mitric oxide analyzer 
NP Nanoparticle 
PDMS Polydimethylsiloxane 
PEG Polyethylene glycol 
PetA 5,12-Dimethyl-7,14-diphenyl-1,4,8,11-tetra-aza-cyclotetradecane. 
phen 1,10-Phenanthroline 
photoCORM Photo-activated CO releasing moiety 
photoNORM Photo-activated NO releasing moiety 
PL Photoluminescence 
PLGA Poly(D,L-lactic-co-glycolic) acid 
Por Porphyrin 
PPIX Protoporphyrin-IX 
py Pyridine 
QD Quantum dot 
Ri photochemical rate 
RBS Roussin’s black salts 
RRS Roussin’s red salt 
RSE Roussin’s red ester 
salen N,N’-ethylenebis(salicylideneiminato)dianion 
Salophen N,N’-1,2-phenylenebis(salicylideneiminato)dianion 
TCF Thiol functionalized derivative of cupferron 
TD-DFT Time-dependent density functional theory 
TMOS Tetramethylorthosilicate 
TPE Two-photon excitation 
TPPTS Tris(sulfonatophenyl)phosphine trianion 
UCNP Upconverting nanoparticle 
UV Ultraviolet 
F quantum yield 
lirr irradiation wavelength 
b two-photon absorption cross section 
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12. Appendix: Discussion of “first order rate laws” in photochemical reactions. 
 Excited states may deactivate by multiple unimolecular pathways including internal 
conversion / intersystem crossing to other excited states, nonradiative or radiative decay to the 
ground state and reaction to products. In addition, one must consider quenching by other species 
including bimolecular energy or electron transfer in solutions or unimolecular energy or electron 
transfer in polychromophoric systems [121]. Elucidating the trajectories, dynamics and 
mechanisms of such pathways, which in many cases are exceedingly fast, requires sophisticated 
application of flash and continuous photolysis techniques, and such issues continue to be of 
active interest to photochemists and photophysicists. 
 This investigator believes that understanding the fundamental mechanisms of excited state 
chemistry is quite relevant to designing better precursors for the photo-uncaging of bioactive 
substances such as the small molecule bioregulators (SMBs) discussed in this article. However, it 
is clear that what drives the activity in this field is the design of new molecules, materials or 
strategies for the delivery of such agents to the targets of interest. The key question in such an 
application is -- Does it work for the intended purpose?  In this context, once the caged SMB (or 
other bioactive compound) is localized at the desired site, the rate and dosage of delivery is of 
crucial importance. For a material that releases the SMB by a unimolecular photochemical 
process, that rate is the product of the quantum yield of SMB uncaging FSMB times the intensity 
of the light absorbed (Iabs) by the SMB precursor (eq. A1)  
  SMB uncaging rate  = d[SMB]/dt = FSMB x Iabs                                               (A1) 
where Iabs is generally defined for solution phase studies in terms of the Einsteins (moles) or 
number of quanta absorbed by the photoreactant per unit volume per unit time [122].   
 The quantum yield Fi is a unit-less efficiency term that can be defined for a specific 
photoprocess i :  
         Fi  =  (number of molecules undergoing process i)/(number of photons absorbed)  (A2) 
This term indicates how excited states initially formed by the light absorption partition between 
the various deactivation and reaction pathways under the specific conditions. For a solution, 
where the photoreactant is the only species absorbing the incident light, Iabs is defined by eq. A3.  
  Iabs =  Ii (1-10-Abs(l))                (A3) 
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where Ii is the incident light intensity. Abs(l) is the solution absorbance of the substrate X at 
irradiation wavelength lirr and equals the product of the molar concentration of X, the molar 
extinction coefficient (el, in L moles-1 cm-1) at lirr and the pathlength l of the cell (in cm).  
 An unfortunate development has been the tendency of some workers in the field to report a 
first order rate constant (kp) for the photochemical SMB uncaging from a specific precursor X (i.e., 
photochemical rate = kp[X]). Such "rate constants" were obtained from exponential plots of 
optical absorbance changes during the course of uncaging. The problem with such plots is that 
the " kp " calculated is an artifact [123]. An obvious argument against treating this as a “first order 
rate constant” is that the value of such a "rate constant" is a function of Ii. Furthermore, when 
[X] is high enough to absorb nearly all the incident light, the rate of the photochemical reaction 
becomes independent of substrate concentration, that is, it is zero order [X]. Thus, there is no 
unimolecular rate constant associated with this process. 
 Figure A1 further illustrates this point using actual experimental data. The initial 
concentration of the substrate X was sufficiently high to give an absorbance of ~2.0 at lirr so that 
~99% of the incident light was absorbed. Continuous photolysis depleted the absorbing substrate 
to give a product that absorbs little at that wavelength. Initially Iabs is nearly constant, thus the 
rate according to eq. 1 is essentially constant. Eventually X is depleted sufficiently that Iabs (and 
thus the rate) decreases with continued photolysis time and presents a curvature in the latter 
stages according to eq. A3. This curvature can be approximated as an exponential, since, when 
Abs(lirr) << 1, the factor (1-10-Abs) @ 2.3(Abs) and thus is directly proportional to [X]. Since the 
precision of most spectrophotometers is optimal at absorbance values < 1, the corresponding 
concentrations are convenient for study. However, any “rate constant” calculated from such 
treatment of the data is an artifact of this feature and is misleading.    
 
Figure. A1. Changes in the absorbed light intensity (Iabs) at the irradiation wavelength as a function of the continuous 
irradiation time for a photoactive compound measured with a power meter. (Taken with permission from the Ph.D. 
Dissertation of Zhi Li, University of California, Santa Barbara, 2017) 
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